Vanguard Portfolio Management’s Castle Biosciences CSTL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$25.5M Sell
716,665
-124,120
-15% -$3.75M ﹤0.01% 1880
2026
Q2
$20.1M Sell
840,785
-20,986
-2% -$467K ﹤0.01% 2000
2026
Q1
$21.2M Buy
+861,771
New +$28.2M ﹤0.01% 1880

Other funds holding CSTL

Vanguard Portfolio Management's CSTL Position: Q3 2026 in Review

Vanguard Portfolio Management reduced its Castle Biosciences (CSTL) stake by 15% in Q3 2026, selling an estimated $3.75M and leaving 716,665 shares worth $25.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1880.

Vanguard Portfolio Management first reported a position in CSTL in Q1 2026 and has held it in 3 quarters since. 202 funds tracked by Wall St. Rank hold CSTL as of Q3 2026.

  • Vanguard Portfolio Management held 716,665 shares of Castle Biosciences worth $25.5M as of Q3 2026.
  • Vanguard Portfolio Management sold 124,120 Castle Biosciences shares in Q3 2026, an estimated $3.75M.
  • Castle Biosciences made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q3 2026, its #1880 holding.
  • Vanguard Portfolio Management first reported a position in Castle Biosciences in Q1 2026 and has held it in 3 quarters since.
  • 202 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2026.

Based on Vanguard Portfolio Management's 13F filing for Q3 2026, filed 13 Nov 2026.